Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma

Leukemia Research

Volumn 32, Issue 8, 2008, Pages 1295-1298

  Hofmeister, C C ^a   Jansak, B ^a   Denlinger, N ^a   Kraut, E H ^a   Benson, D M ^a   Farag, S S ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arsenic; Doxorubicin; Multiple myeloma; Vincristine

Indexed keywords

ARSENIC TRIOXIDE; DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEMOGRAPHY; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; FATIGUE; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPONATREMIA; LOBAR PNEUMONIA; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DEXAMETHASONE; DOXORUBICIN; DRUG EVALUATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; OXIDES; TREATMENT OUTCOME; VINCRISTINE;

EID: 43049117226     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.10.020     Document Type: Article

References (12)

1. Rifkin R.M., Gregory S.A., Mohrbacher A., Hussein M.A., Rifkin R.M., Gregory S.A., et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 106 4 (2006) 848-858
2. Munshi N.C., Tricot G., Desikan R., Badros A., Zangari M., Toor A., et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16 9 (2002) 1835-1837
3. Wang W., Qin S.K., Chen B.A., and Chen H.Y. Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World J Gastroenterol 7 5 (2001) 702-705
4. Ling Y.H., Jiang J.D., Holland J.F., and Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Molecular pharmacology 62 3 (2002) 529-538
5. Gartenhaus R.B., Prachand S.N., Paniaqua M., Li Y., and Gordon L.I. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8 2 (2002) 566-572
6. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
7. Blade J., Samson D., Reece D., Apperley J., Bjorkstrand B., Gahrton G., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 5 (1998) 1115-1123
8. Durie B.G., Harousseau J.L., Miguel J.S., Blade J., Barlogie B., Anderson K., et al. International uniform response criteria for multiple myeloma. Leukemia 20 9 (2006) 1467-1473
9. Dai J., Weinberg R.S., Waxman S., and Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93 1 (1999) 268-277
10. Grad J.M., Bahlis N.J., Reis I., Oshiro M.M., Dalton W.S., and Boise L.H. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98 3 (2001) 805-813
11. Berenson J., Boccia R., Siegel D., Bozdech M., Bessudo A., Stadtmauer E., et al. A Multicenter Phase II Study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) for patients with relapsed or refractory multiple myeloma. Blood 106 11 (2005) 2564
12. Berenson J.R., Matous J.V., Ferretti D., Swift R.A., Mapes R.A., Morrison B., et al. A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma. J Clin Oncol 24 18_suppl (2006) 7611